Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00661_DB01076_nanopub.RAFRpif2PFkmtKkMi096bqIMcn9Kj9tMhKI5L5liT5cqU#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00661_DB01076 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00661_DB01076 label "DDI between Verapamil and Atorvastatin - Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Atorvastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce lovastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Atorvastatin if Verapamil is initiated, discontinued or dose changed. [drugbank_resource:DB00661_DB01076]" assertion.
- drugbank_resource:DB00661_DB01076 identifier "drugbank_resource:DB00661_DB01076" assertion.
- drugbank_resource:DB00661_DB01076 title "DDI between Verapamil and Atorvastatin - Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Atorvastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce lovastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Atorvastatin if Verapamil is initiated, discontinued or dose changed." assertion.
- drugbank:DB00661 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00661_DB01076 assertion.
- drugbank:DB01076 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00661_DB01076 assertion.